Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2017-12-07 |
Bluebird bio (USA - MA) TC BioPharm (UK) |
gamma delta CAR T cells |
hematological cancers, solid tumors |
research - development - R&D |
Cancer - Oncology |
Development agreement |
2017-12-06 |
Servier (France) Vernalis (UK) |
drugs for a new undisclosed target |
|
R&D - research |
Cancer - Oncology |
Milestone |
2017-12-06 |
Nosopharm (France) |
member of the supervisory board |
|
nomination |
Infectious diseases |
Nomination |
2017-12-06 |
Juno Therapeutics (USA - WA) Fred Hutchinson Cancer Research Center (USA - WA) OncoTracker (USA - CA) |
combinations of gamma secretase inhibitors (GSIs) and BCMA-directed engineered T cells |
multiple myeloma |
licensing |
Cancer - Oncology |
Licensing agreement |
2017-12-06 |
Tapimmune (USA - FL) |
chief medical officer |
|
nomination |
Cancer - Oncology |
Nomination |
2017-12-06 |
BioInvent (Sweden) Transgene (France) |
oncolytic virus candidates encoding an anti-CTLA-4 antibody sequence |
|
development |
Cancer - Oncology |
Development agreement |
2017-12-05 |
Crossbeta Biosciences (The Netherlands) Probiodrug (Germany) |
biomarkers |
Alzheimer's disease |
collaboration |
Neurodegenerative diseases |
Collaboration agreement |
2017-12-05 |
Juno Therapeutics (USA - WA) Eli Lilly (USA - IN) |
LY3039478 |
multiple myeloma |
licensing |
Cancer - Oncology |
Licensing agreement |
2017-12-05 |
Shire (UK - USA) Rani Therapeutics (USA - CA) |
Rani Pill™ technology for the oral delivery of factor VIII (FVIII) therapy |
hemophilia A |
research - licensing |
Rare diseases - Genetic diseases - Hematological diseases |
Research agreement |
2017-12-04 |
Cellectis (France) |
vice-president |
|
nomination |
Cancer - Oncology - Rare diseases |
Nomination |
2017-12-04 |
Cellectis (France) |
vice-president - chief medical officer |
|
nomination |
Cancer - Oncology - Rare diseases |
Nomination |
2017-12-04 |
Idorsia (Switzerland) Janssen Biotech, a J&J company (USA - NJ) |
aprocitentan (ACT-132577) |
|
development - commercialisation |
|
Collaboration agreement |
2017-12-01 |
Shire (UK - USA) |
chief scientific officer, chief medical officer |
|
nomination |
|
Nomination |
2017-11-30 |
Orchard Therapeutics (UK) |
new facility in the San Francisco Bay Area |
|
opening of new premises |
Rare diseases - Genetic diseases |
Opening of new premises |
2017-11-29 |
Illumina (USA - CA) |
Solutions Center on the Genopole Campus in Évry |
|
establishment of a new subsidiary in the EU |
Technology - Services |
Establishment of a new subsidiary in the EU |
2017-11-29 |
Bluebird bio (USA - MA) |
manufacturing facility in Durham |
|
plant acquisition |
|
Plant acquisition |
2017-11-28 |
Synpromics (UK) UCL (UK) |
synthetic gene promoters |
Parkinson's disease |
research - development - R&D |
Neurodegenerative diseases |
Development agreement |
2017-11-27 |
Philips (The Netherlands) Stratasys (USA - MN) 3D Systems (USA - IL) |
advanced 3D modeling applications for radiologists |
|
collaboration |
Technology - Services |
Collaboration agreement |
2017-11-27 |
Biomarin Pharmaceutical (USA - CA) undisclosed |
Rare Pediatric Disease Priority Review Voucher (PRV) |
|
commercialisation |
Rare diseases |
Commercialisation agreement |
2017-11-27 |
Orchard Therapeutics (UK) the University of Manchester (UK) |
lentivirus-based autologous ex-vivo gene therapy |
mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) |
licensing |
Rare diseases - Genetic diseases |
Licensing agreement |